Smoking status and vascular risk factors as predictors of disability in AQP4-NMOSD and MOGAD.
Chan F. et al, (2025), Mult Scler
Toward European harmonization of national myasthenia gravis registries: modified Delphi procedure-based expert consensus on collectable data.
Slioui A. et al, (2025), Orphanet J Rare Dis, 20
The role of N-glycans in regulatory T cells in autoimmunity.
Carneiro P. et al, (2025), Autoimmun Rev, 24
Clinical data and reporting quality in NMDAR-antibody encephalitis and pregnancy: a systematic review
Harris SL. et al, (2025), BMJ Neurology Open, 7, e001005 - e001005
Quantitative Contribution of Clinical Attacks to Residual Disability in Patients With AQP4-Antibody Neuromyelitis Optica Spectrum Disorder.
Chen B. et al, (2025), Neurology, 104
Efgartigimod efficacy and safety in refractory myasthenia gravis: UK's first real-world experience.
Moniz Dionísio J. et al, (2025), J Neurol Neurosurg Psychiatry
Progressive Encephalomyelitis with Rigidity and Myoclonus (PERM) Associated with GlyR Antibody in an APECED Patient.
Ochoa S. et al, (2024), J Clin Immunol, 45
The influence of MOGAD on diagnosis of multiple sclerosis using MRI
Geraldes R. et al, (2024), Nature Reviews Neurology
Retinal Changes in Double-Antibody Seronegative Neuromyelitis Optica Spectrum Disorders.
Oertel FC. et al, (2024), Neurol Neuroimmunol Neuroinflamm, 11
Study of seasonality of attacks in MOG antibody-associated disease.
Francis A. et al, (2024), Mult Scler Relat Disord, 90
Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis.
Arnett S. et al, (2024), J Neurol
Characterizing mortality in patients with AQP4-Ab+ neuromyelitis optica spectrum disorder.
Francis A. et al, (2024), Ann Clin Transl Neurol
MOG-IgA as a Potential Marker of Germinal Center Activity
Handel AE. et al, (2024), JAMA Neurology, 81, 297 - 297
Usability of the zilucoplan prefilled syringe for the treatment of generalized myasthenia gravis: insights from a human factors validation study
Domanska B. et al, (2024), Expert Review of Medical Devices
Do Early Relapses Predict the Risk of Long-Term Relapsing Disease in an Adult and Paediatric Cohort with MOGAD?
Chen B. et al, (2023), Ann Neurol, 94, 508 - 517
The effect of smoking on MRI lesion resolution in NMOSD-AQP4 and MOGAD.
Berhanu D. et al, (2023), Mult Scler, 29, 1250 - 1256
International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab.
Paul F. et al, (2023), Neurol Neuroimmunol Neuroinflamm, 10
A systematic literature review to examine the considerations around pregnancy in women of child-bearing age with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) or aquaporin 4 neuromyelitis optica spectrum disorder (AQP4+ NMOSD).
Leite MI. et al, (2023), Mult Scler Relat Disord, 75